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Window of Opportunity*
lice K. Jacobs, MD
oston, Massachusetts
uring the past several decades, there have been numerous
tudies evaluating sex-based differences in patients under-
oing coronary revascularization across the clinical spectrum
f coronary artery disease, reporting remarkably consistent
ndings (1). Yet, the number and rate of studies comparing
utcomes between women and men undergoing percutane-
us coronary intervention (PCI) continue to increase, per-
aps driven by the increasing awareness of the prevalence
nd adverse impact of coronary disease in women, by the
andate to include more women and sex-specific analyses
n clinical trials, and by the lack of true understanding of the
iologic basis for the differences observed.
See page 603
Notably, in the more recent studies, the sex difference in
adjusted) in-hospital mortality has nearly disappeared, even
n large-scale registries, which are less likely to be under-
owered (on the basis of the 25% to 30% of patients who are
omen) (2). However, the incidence of bleeding and vas-
ular complications after the procedure continues to be
ignificantly higher in women than in men (3). Moreover,
oth women and men in contemporary studies have, in
omparison with earlier studies, more complex anatomy and
oncomitant disease. Yet, adjusted mortality after the pro-
edure has decreased, particularly in women (4,5). The
easons for the reduction in the sex difference in mortality
re unclear, but greater awareness of issues specific to
omen (such as peri-procedural heart failure due to hyper-
ensive heart disease) and improved technology including
maller and more flexible stents (allowing access to smaller
oronary vessels) have been implicated.
In fact, when coronary stents were initially introduced
nto clinical practice, it was hoped that they would negate
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-w
ions or the American College of Cardiology.
From the Section of Cardiology, Boston Medical Center, Boston, Massachusetts.he marked increase in mortality in women compared with
en after balloon angioplasty (adjusted in-hospital mortal-
ty 5-fold higher in women within the 1985 to 1986
ational Heart, Lung and Blood Institute’s Coronary An-
ioplasty Registry) (6). Not surprisingly (because stents have
arely been shown to save lives), at least initially, stents did
ot fulfill this promise. For patients undergoing PCI with
tents, the sex difference in in-hospital (7) and 30-day (8)
ortality persisted in the setting of both acute myocardial
nfarction (MI) and elective/urgent procedures. However,
he benefits of stents in reducing repeat revascularization are
ndependent of sex. For patients treated with both bare-
etal (BMS) (9) and drug-eluting (DES) (sirolimus [10] and
aclitaxel [11]) stents, the reduction in restenosis and repeat
arget vessel (TVR) and target lesion revascularization have
een reported to be similar in women and men (12).
In this issue of JACC: Cardiovascular Interventions,
numa et al. (13) add to the growing body of evidence
emonstrating improved outcomes in women (and men)
ndergoing PCI with DES and extend the observations to
nclude longer-term follow-up. In a retrospective cohort
tudy of 4,936 consecutive patients (of whom 1,394 or
8.2% were women) treated with PCI with stents within the
ESEARCH (Rapamycin-Eluting Stent Evaluated at Rot-
erdam Cardiology Hospital) and T-SEARCH (Taxus-
tent Evaluated at Rotterdam Cardiology Hospital) regis-
ries between 2000 and 2004, the sex differences in
utcomes as well as the outcomes in women and men
eceiving BMS in comparison with DES were evaluated
uring the 3 years after the procedure.
As expected, for both BMS and DES groups, women
ere significantly older (5 years), with a higher risk profile
nd a lower prevalence of multi-vessel disease than men. In
ddition, the number of lesions treated, the number of
tents, and total stent length were similar between women
nd men. Cumulative incidences of clinical end points
hrough 3 years revealed the absence of a significant differ-
nce by sex for rates of all-cause death, MI, TVR, stent
hrombosis, and major adverse cardiovascular event
MACE), although there was a trend toward a higher
ortality in women in both stent groups at 1 year.
Among both women and men, there was a higher
revalence of risk factors, more complex coronary anatomy
reated, and more frequent treatment for acute MI in the
ES compared with the BMS group. Moreover, patients
reated with DES had a longer stent length and more stents
sed although the average stent diameter was smaller in
omparison with patients receiving BMS. Yet, rates of
ACE and TVR were lower in both women and men
reated with DES in comparison with BMS at any time
oint throughout 3 years of follow-up. However, subgroup
ultivariate analysis revealed a higher risk of MACE in
omen compared with men with acute MI treated with
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612ES (hazard ratio: 1.37, 95% confidence interval: 1.02 to
.85).
These experienced investigators who have significantly
ontributed to our understanding of the use of both BMS
nd DES in an evolving clinical practice have both con-
rmed and extended the observations of improved outcomes
n women, absence of sex-based differences in MACE, and
imilar efficacy of DES in both sexes in patients undergoing
ontemporary PCI—the lack of propensity-matched sam-
les for sex as well as type of stent and the absence of
ultivariate adjustment for left ventricular function and
hanges in the standard of care over time notwithstanding.
Several interesting observations have emerged from these
nalyses. Although the limitations of subgroup analyses
particularly when not pre-specified) and the small number
f patients undergoing PCI for acute MI are well-
ecognized, the data suggest a significantly higher incidence
f MACE in women compared with men receiving DES in
his setting. These findings are consistent with other studies
eporting sex differences in outcomes after ST-segment
levation myocardial infarction with higher in-hospital
ortality in women in comparison with men (14). It should
e noted, however, that the influence of time to treatment,
hich has been shown to be longer in women, and the use
f guideline-recommended medical therapies that have been
hown to be used less often in women were not measured in
his study.
The observation that the benefits of DES are indepen-
ent of sex is particularly encouraging. Although women
ave a higher prevalence of diabetes, diffuse coronary
isease, and small vessels in comparison with men, the
mpact of these factors on the sex-difference in the incidence
f restenosis after PCI has been variable, with some studies
eporting a lower risk in women (15). The findings might be
onfounded by exclusion of women in many studies on the
asis of these characteristics—their smaller, calcified, and
iffusely diseased vessels that are often not ideally suited for
CI. Furthermore, it has been shown that the macrovascu-
ature and microvasculature are stiffer and smaller and that
here is more endothelial and smooth muscle dysfunction in
omen than in men (16). There are also data to suggest that
strogen attenuates the vessel wall response to injury, in part
y reducing the rate of oxidative degradation of arterial wall
itric oxide and by promoting prostatcyclin formation and
asodilation (17,18). However, the potential contribution of
hese findings to clinical studies is unclear, particularly in
he absence of information concerning the prevalence of
ormone replacement therapy in the majority of trials.
Perhaps most important is that the efficacy of DES in
educing restenosis and repeat revascularization in women
pens a window of opportunity. The development of
evice-based local drug delivery strategies could decrease the
dverse impact of inherent sex-differences in pharmacody-
amics and reduced glomerular filtration rate and delayedastric emptying reported in women in comparison with
en (19). This approach might, depending on the agents
sed, decrease the risk of bleeding and excess dosing of
rugs seen more frequently in women (20). Ultimately,
ex-based therapeutic strategies might emerge, perhaps
ctually initially developed in women and then translated to
en, and lead to improved care and outcomes for all
atients undergoing coronary revascularization in the years
head.
eprint requests and correspondence: Dr. Alice K. Jacobs,
ection of Cardiology, Boston Medical Center, 88 East Newton
treet, Boston, Massachusetts 02118. E-mail: alice.jacobs@
mc.org.
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